Bank of America
ZYBT

Bank of America’s Zhengye Biotechnology Holding ZYBT Stock Holding History

Bank of America’s Portfolio ZYBT Stock Details ZYBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-73
Closed -$436 – 8795
2025
Q2 		$436 Buy
+73
New +$580 ﹤0.01% 7695

Other funds holding ZYBT

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Bank of America's ZYBT Position: Q3 2025 in Review

Bank of America sold out of Zhengye Biotechnology Holding (ZYBT) in Q3 2025, closing a stake of 73 shares — an estimated $436 sold.

Bank of America first reported a position in ZYBT in Q2 2025 and held it in 1 quarter. The position peaked at $436 in Q2 2025. 10 funds tracked by Wall St. Rank hold ZYBT as of Q3 2025.

  • Bank of America reported no remaining Zhengye Biotechnology Holding position as of Q3 2025 after selling out during the quarter.
  • Bank of America sold 73 Zhengye Biotechnology Holding shares in Q3 2025, an estimated $436.
  • Bank of America first reported a position in Zhengye Biotechnology Holding in Q2 2025 and held it in 1 quarter.
  • Bank of America's Zhengye Biotechnology Holding position peaked at $436 in Q2 2025.
  • 10 funds tracked by Wall St. Rank held Zhengye Biotechnology Holding as of Q3 2025.

Based on Bank of America's 13F filing for Q3 2025, filed 14 Nov 2025.